Falcon’s Beyond Reports Second Quarter 2026 Financial Results

Falcon's Beyond Global, Inc. (FBYD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Falcon’s Beyond Reports Second Quarter 2026 Financial Results Company Reports Consolidated Revenue of $5.6 Million for Q2 Company's Unconsolidated Subsidiary, Falcon's Creative Group, generated Q2 revenue of $12.5 Million Company's Unconsolidated Joint Venture, Produ

Event · Earnings
Original reporting
Published Aug 13, 2026, 11:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 11:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$FBYD
Bearish
medium confidence
Mentioned
$FBYD
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$FBYDBearishMed
01

Why it matters

Traders can reassess FBYD’s near-term fundamentals using the newly reported quarterly revenue, net loss, Adjusted EBITDA loss, and segment pipeline commentary. The filing also reiterates going-concern and liquidity-related risk language in the forward-looking statements.

02

Market read

Fresh quarterly numbers and pipeline commentary can move sentiment for FBYD, but the continued net loss and large Adjusted EBITDA loss likely cap upside expectations.

03

What to watch

Adjusted EBITDA excludes specific items (including a $4.0M reversal and other gains), and the filing highlights liquidity/going-concern risk in forward-looking statements, which may dominate trading more than the headline revenue growth.

Relevance 7/10Novelty 8/10Timing: filed pre-market today (Aug 13, 2026) with Q2 2026 results

Background

This is an SEC 8-K with Exhibit 99.1 reporting Falcon’s Beyond Global’s Q2 2026 results and business highlights, including pipeline figures for its Attractions segment and equity-method results from its joint venture.

Company-level read

Ticker impact

$FBYDBearishMedium confidence
Context

Falcon’s Beyond reported Q2 2026 consolidated revenue of $5.6M, net loss of $0.3M, and Adjusted EBITDA loss of $5.2M in an 8-K.

Expected impact

Likely negative-to-neutral near term, given the reported net loss and large Adjusted EBITDA loss despite revenue growth.

Evidence & confidence

Revenue more than doubled, but profitability metrics remain weak (net loss and Adjusted EBITDA loss). The only operational positive is a first major design and build contract added to the Attractions pipeline, but no size or margin detail is provided.

Market effects

Adds datapoints on entertainment and experience-economy monetization and the gap between revenue growth and EBITDA losses for small-cap operators.

No clear regional spillover beyond Orlando-based issuer disclosure.

Limited; includes an international joint venture (Meliá) but no broader macro or cross-border regulatory change.

Counterpoint

Revenue more than doubled and the Attractions business added its first major design and build contract to a $28.4M pipeline, which could translate into future margin expansion if execution improves.

Key entities

  • Falcon’s Beyond Global, Inc.

    Nasdaq-listed entertainment and technology enterprise reporting Q2 2026 financial results on Form 8-K.

  • Falcon’s Creative Group (FCG)

    Equity-method investment division reporting $12.5M revenue and $0.4M net income for Q2 2026, with Falcon’s share of net loss after preferred return and amortization.

  • Producciones de Parques (PDP)

    50:50 joint venture with Meliá Hotels International reporting $6.5M revenue and $0.4M operating and net income for Q2 2026.

  • Meliá Hotels International

    Co-owner of the PDP joint venture referenced in the results release.

Related articles

$FBYDMed

Falcon’s Beyond Reports Third Quarter 2026 Financial Results

Falcon's Beyond Global, Inc. (FBYD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Falcon’s Beyond Reports Third Quarter 2026 Financial Results Company Reports Consolidated Revenue of $7.3 Million for Q3 , an 80% increase over prior year. Company's Unconsolidated Subsidiary, Falcon's Creative Group, generated Q3 revenue of $5.2 Million Company's Un

$NMAXMed

Why Newsmax Stock Popped on Friday

Newsmax (NMAX) shares rose 31% after reporting Q3 revenue of $69M, up 52.5% YoY, and net income of $15.2M. The company cited strong audience engagement and growth in high-margin revenue streams. CEO Christopher Ruddy expects continued growth ahead of the presidential election.

$LUNRMed

What Is Driving Intuitive Machines Stock?

Intuitive Machines (LUNR) shares rose 7.0% on Nov 12, 2026, after reporting Q3 revenue of $269M, beating estimates. The company's loss of $0.10 per share met expectations, while gross margin improved to 26%. Free cash flow turned positive at $33M, a company record. Management raised full-year revenue guidance to $920M-$950M. The stock's performance contrasted with broader industry declines.

$RMIXMedAI 8/10

Suncrete (RMIX) Q3 2026 Earnings Call Transcript

Suncrete (RMIX) reported Q3 2026 revenue of $141M, up 45% QoQ and 163% YoY. Adjusted EBITDA rose 66% QoQ to $22.4M. The company lowered its full-year outlook due to residential construction weakness but remains confident in long-term demand. Acquisition integration is progressing, with North Texas showing margin improvement. Suncrete expects $200M-$250M revenue from 2026 acquisitions in 2027. The company has $206.5M in total liquidity.

$CLLSMed

Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene

Cellectis SA (CLLS) discussed its strategic shift to gene editing during its Q3 2026 earnings call. Management highlighted the selection of APOC3 over ANGPTL3 for triglyceride reduction, with plans to start Phase 1 dosing by end-2027. The company reported $149M in cash as of September 30, 2026, with a runway into H2 2028. Revenue decreased to $19.9M from $67.4M YoY, while R&D expenses increased to $108.8M from $69.1M, driven by the AstraZeneca collaboration.